This activity has expired. Credit is no longer available.
This activity is supported by independent educational grants from AstraZeneca and Bristol-Myers Squibb.

Mismatch Repair Deficient (dMMR) and Microsatellite Instability-High (MSI-H) Tumors

Laura J. Zitella, MS, RN, ACNP-BC, AOCN®
Stanford Health Center

The use of immune checkpoint inhibitors is emerging as an effective strategy to treat patients with mismatch repair–deficient and microsatellite instability–high tumors. This presentation summarizes data on currently available immunotherapeutic agents for these tumors and details the appropriate management of immune-related hypothyroidism.


Download Slides

These activities, certified for CME/CE/CPE credit, are jointly provided by

Annenberg Logo Harborside Press Logo

in collaboration with

Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.